Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A non-standardized **multi-allergen extract** containing karaya gum, acacia, cat flea, dog flea, and tragacanth allergenic material. It is intended for clinician-supervised allergen-specific immunotherapy in patients with documented sensitization and relevant exposure, with the aim of reducing allergic responses through controlled repeated allergen exposure. The product is supplied as an injectable allergenic-extract solution and is associated with subcutaneous administration; allergenic extracts can cause severe systemic reactions, including anaphylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on karaya gum + acacia + ctenocephalides felis + ctenocephalides canis + tragacanth.